Cargando…

Reciprocal Induction of MDM2 and MYCN in Neural and Neuroendocrine Cancers

MYC family oncoproteins MYC, MYCN, and MYCL are deregulated in diverse cancers and via diverse mechanisms. Recent studies established a novel form of MYCN regulation in MYCN-overexpressing retinoblastoma and neuroblastoma cells in which the MDM2 oncoprotein promotes MYCN translation and MYCN-depende...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tran, Hung N., Singh, Hardeep P., Guo, Wenxuan, Cambier, Linda, Riggan, Luke, Shackleford, Gregory M., Thornton, Matthew E., Grubbs, Brendan H., Erdreich-Epstein, Anat, Qi, Dong-Lai, Cobrinik, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7793692/ https://www.ncbi.nlm.nih.gov/pubmed/33425720 http://dx.doi.org/10.3389/fonc.2020.563156

Ejemplares similares

MDM2 but not MDM4 promotes retinoblastoma cell proliferation through p53-independent regulation of MYCN translation
por: Qi, Dong-Lai, et al.
Publicado: (2016)

GRK2 promotes growth of medulloblastoma cells and protects them from chemotherapy-induced apoptosis
por: Pathania, Anup S., et al.
Publicado: (2019)

An immature, dedifferentiated, and lineage-deconstrained cone precursor origin of N-Myc–initiated retinoblastoma
por: Singh, Hardeep P., et al.
Publicado: (2022)

Molecular mechanisms of MYCN-dependent apoptosis and the MDM2–p53 pathway: an Achille’s heel to be exploited for the therapy of MYCN-amplified neuroblastoma
por: Petroni, Marialaura, et al.
Publicado: (2012)

Continuous and bolus intraventricular topotecan prolong survival in a mouse model of leptomeningeal medulloblastoma
por: Shackleford, Gregory M., et al.
Publicado: (2019)

PID1 increases chemotherapy-induced apoptosis in medulloblastoma and glioblastoma cells in a manner that involves NFκB
por: Xu, Jingying, et al.
Publicado: (2017)

MDM2 regulates MYCN mRNA stabilization and translation in human neuroblastoma cells
por: Gu, Lubing, et al.
Publicado: (2011)

MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63
por: Gamble, Laura D., et al.
Publicado: (2011)

Editorial: Developmental therapeutics in pediatric neuro-oncology
por: Makimoto, Atsushi, et al.
Publicado: (2023)

Addiction of MYCN Amplified Tumours to B-MYB Underscores a Reciprocal Regulatory Loop
por: Gualdrini, Francesco, et al.
Publicado: (2010)

BarTeL, a Genetically Versatile, Bioluminescent and Granule Neuron Precursor-Targeted Mouse Model for Medulloblastoma
por: Shackleford, Gregory M., et al.
Publicado: (2016)

MYCN and the epigenome
por: He, Stanley, et al.
Publicado: (2013)

c-Abl Is an Upstream Regulator of Acid Sphingomyelinase in Apoptosis Induced by Inhibition of Integrins αvβ3 and αvβ5
por: Ren, Xiuhai, et al.
Publicado: (2012)

The ELAVL3/MYCN positive feedback loop provides a therapeutic target for neuroendocrine prostate cancer
por: Ji, Yiyi, et al.
Publicado: (2023)

MYCN is amplified during S phase, and c-myb is involved in controlling MYCN expression and amplification in MYCN-amplified neuroblastoma cell lines
por: Aygun, Nevim, et al.
Publicado: (2019)

Implementation of the plasma MYCN/NAGK ratio to detect MYCN amplification in patients with neuroblastoma
por: Su, Yan, et al.
Publicado: (2020)

MYCN upregulates the transsulfuration pathway to suppress the ferroptotic vulnerability in MYCN-amplified neuroblastoma
por: Floros, Konstantinos V., et al.
Publicado: (2022)

MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma
por: Agarwal, Saurabh, et al.
Publicado: (2018)

Therapeutic potential of targeting MYCN: A case series report of neuroblastoma with MYCN amplification
por: Huang, Can, et al.
Publicado: (2020)

A MYCN-independent mechanism mediating secretome reprogramming and metastasis in MYCN-amplified neuroblastoma
por: Zhang, Hai-Feng, et al.
Publicado: (2023)

Induction of MYCN-amplified neuroblastoma differentiation through NMYC suppression using PPAR-γ antagonist
por: Nakao-Ise, Yukako, et al.
Publicado: (2023)

Correlation Between MYCN Gene Status and MYCN Protein Expression in Neuroblastoma: A Pilot Study To Propose the Use of MYCN Immunohistochemistry in Limited-Resource Areas
por: Santiago, Teresa, et al.
Publicado: (2019)

CHRM4/AKT/MYCN upregulates interferon alpha-17 in the tumor microenvironment to promote neuroendocrine differentiation of prostate cancer
por: Wen, Yu-Ching, et al.
Publicado: (2023)

The MYCN Protein in Health and Disease
por: Ruiz-Pérez, María Victoria, et al.
Publicado: (2017)

MYCN Function in Neuroblastoma Development
por: Otte, Jörg, et al.
Publicado: (2021)

MYCN and Metabolic Reprogramming in Neuroblastoma
por: Bansal, Mohit, et al.
Publicado: (2022)

Metastasis in neuroblastoma: the MYCN question
por: Bhavsar, Swapnil Parashram
Publicado: (2023)

MYCN-targeting miRNAs are predominantly downregulated during MYCN-driven neuroblastoma tumor formation
por: Beckers, Anneleen, et al.
Publicado: (2014)

Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors
por: Vaughan, Lynsey, et al.
Publicado: (2016)

Correction: MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma
por: Agarwal, Saurabh, et al.
Publicado: (2018)

Elimination of MYCN-Amplified Neuroblastoma Cells by Telomerase-Targeted Oncolytic Virus via MYCN Suppression
por: Tanimoto, Terutaka, et al.
Publicado: (2020)

An ALYREF-MYCN coactivator complex drives neuroblastoma tumorigenesis through effects on USP3 and MYCN stability
por: Nagy, Zsuzsanna, et al.
Publicado: (2021)

FOXR2 Stabilizes MYCN Protein and Identifies Non–MYCN-Amplified Neuroblastoma Patients With Unfavorable Outcome
por: Schmitt-Hoffner, Felix, et al.
Publicado: (2021)

SMAD9-MYCN positive feedback loop represents a unique dependency for MYCN-amplified neuroblastoma
por: Tan, Kezhe, et al.
Publicado: (2022)

Destabilization of MYC/MYCN by the mitochondrial inhibitors, metaiodobenzylguanidine, metformin and phenformin
por: WANG, STEPHANIE S., et al.
Publicado: (2014)

Nardostachys jatamansi Root Extract Modulates the Growth of IMR-32 and SK-N-MC Neuroblastoma Cell Lines Through MYCN Mediated Regulation of MDM2 and p53
por: Suryavanshi, Snehal, et al.
Publicado: (2017)

Dangerous liaisons: MYCN meets condensins
por: Achar, Yathish Jagadheesh, et al.
Publicado: (2014)

Editorial: Targeting MYCN in Pediatric Cancers
por: Sala, Arturo
Publicado: (2015)

MYCN-mediated murine cancer models
por: Althoff, Kristina, et al.
Publicado: (2017)

Molecular Mechanisms of MYCN Dysregulation in Cancers
por: Liu, Ruochen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_h9fl5sbm568bjprj7lpb43js1m